MX2022015525A - Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos. - Google Patents
Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos.Info
- Publication number
- MX2022015525A MX2022015525A MX2022015525A MX2022015525A MX2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A
- Authority
- MX
- Mexico
- Prior art keywords
- cyclohexyl
- ylsulfanyl
- ureido
- thiazol
- propoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/023—Preparation; Separation; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063035996P | 2020-06-08 | 2020-06-08 | |
| PCT/US2021/036084 WO2021252311A1 (en) | 2020-06-08 | 2021-06-07 | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015525A true MX2022015525A (es) | 2023-03-23 |
Family
ID=78845832
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015525A MX2022015525A (es) | 2020-06-08 | 2021-06-07 | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos. |
| MX2025012174A MX2025012174A (es) | 2020-06-08 | 2022-12-06 | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxiciclohexil)ureido]tiazol-5-ilsulfanil}-acetico y usos de los mismos |
| MX2025012175A MX2025012175A (es) | 2020-06-08 | 2022-12-06 | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxiciclohexil)ureido]tiazol-5-ilsulfanil}-acetico y usos de los mismos |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025012174A MX2025012174A (es) | 2020-06-08 | 2022-12-06 | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxiciclohexil)ureido]tiazol-5-ilsulfanil}-acetico y usos de los mismos |
| MX2025012175A MX2025012175A (es) | 2020-06-08 | 2022-12-06 | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxiciclohexil)ureido]tiazol-5-ilsulfanil}-acetico y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12479808B2 (enExample) |
| EP (1) | EP4161640A4 (enExample) |
| JP (2) | JP2023530786A (enExample) |
| KR (1) | KR20230048502A (enExample) |
| CN (2) | CN121591674A (enExample) |
| AU (1) | AU2021289309A1 (enExample) |
| CA (1) | CA3181722A1 (enExample) |
| MX (3) | MX2022015525A (enExample) |
| WO (1) | WO2021252311A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093025A1 (en) | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| US12479808B2 (en) | 2020-06-08 | 2025-11-25 | Vtv Therapeutics Llc | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB771147A (en) | 1954-06-04 | 1957-03-27 | Merck & Co Inc | Derivatives of urea |
| ZA6706928B (enExample) | 1967-03-23 | |||
| CH493195A (de) | 1968-01-23 | 1970-07-15 | Ciba Geigy | Schädlingsbekämpfungsmittel |
| GB1195672A (en) | 1968-02-01 | 1970-06-17 | Mobil Oil Corp | Novel Urea Derivatives and Herbicides containing the same |
| CH498859A (de) | 1968-07-17 | 1970-11-15 | Agripat Sa | Verfahren zur Herstellung von Thiadiazolyl-harnstoffen |
| GB1318291A (en) | 1970-04-15 | 1973-05-23 | Shell Int Research | Carboxamide derivatives and fungicidal compositions containing them |
| NL7106557A (enExample) | 1970-06-15 | 1971-12-17 | ||
| IL72093A0 (en) | 1983-06-20 | 1984-10-31 | Lilly Co Eli | N'-substituted(3-alkyl-5-isothiazolyl)urea derivatives |
| IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US6579314B1 (en) | 1995-03-10 | 2003-06-17 | C.R. Bard, Inc. | Covered stent with encapsulated ends |
| AU1735497A (en) | 1996-02-26 | 1997-09-10 | Sumitomo Pharmaceuticals Company, Limited | Sulfonylureidopyrazole derivatives |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| DE69834052T2 (de) | 1997-11-14 | 2006-11-02 | Kowa Co., Ltd., Nagoya | Neue amidverbindungen und medikamente die diese enthalten |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| CN1332726A (zh) | 1998-11-02 | 2002-01-23 | 卫福有限公司 | 吡咯烷化合物及其药物用途 |
| US6500817B1 (en) | 1999-03-08 | 2002-12-31 | Bayer Aktiengesellschaft | Thiazolyl urea derivatives and their utilization as antiviral agents |
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| HK1046139B (zh) | 1999-03-29 | 2004-12-10 | 霍夫曼-拉罗奇有限公司 | 葡糖激酶活化剂 |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US6503949B1 (en) | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
| BR0012068A (pt) | 1999-06-30 | 2002-05-14 | Daiichi Seiyaku Co | Compostos inibidores de vla-4 |
| DE60008550T2 (de) | 1999-09-09 | 2004-08-05 | Kumiai Chemical Industry Co., Ltd. | Pyrimidinderivate und herbizide welche diese enthalten |
| US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| PL357099A1 (en) | 2000-02-07 | 2004-07-12 | Abbott Gmbh & Co.Kg | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| US6608038B2 (en) | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| EP1282612B1 (en) | 2000-05-03 | 2004-12-29 | F. Hoffmann-La Roche Ag | Alkynyl phenyl heteroaromatic glucokinase activators |
| ATE304011T1 (de) | 2000-05-03 | 2005-09-15 | Hoffmann La Roche | Hydantoin-enthaltende glucokinase aktivatoren |
| MXPA02010795A (es) | 2000-05-08 | 2003-03-27 | Hoffmann La Roche | Activadores de glucocinasa de fenilamida sustituida por para-amino. |
| BR0110704A (pt) | 2000-05-08 | 2003-01-28 | Hoffmann La Roche | Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase |
| CA2416229C (en) | 2000-07-20 | 2007-09-18 | F. Hoffmann-La Roche Ag | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
| US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| EP1341774B1 (en) | 2000-12-06 | 2006-02-01 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
| KR101018318B1 (ko) | 2001-12-21 | 2011-03-04 | 노보 노르디스크 에이/에스 | Ｇｋ 활성제로서의 아미드 유도체 |
| CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
| WO2004076420A1 (ja) | 2003-02-26 | 2004-09-10 | Banyu Pharmaceutical Co., Ltd. | ヘテロアリールカルバモイルベンゼン誘導体 |
| US7111188B2 (en) | 2003-07-31 | 2006-09-19 | International Business Machines Corporation | Dynamically configurable fault tolerance in autonomic computing with multiple service points |
| BRPI0506662B8 (pt) | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
| EP1721314A1 (en) | 2004-02-26 | 2006-11-15 | Koninklijke Philips Electronics N.V. | Multiple-spiral hybrid disc for e-book applications |
| US7514448B2 (en) | 2004-04-02 | 2009-04-07 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
| EP1758611A2 (en) | 2004-06-17 | 2007-03-07 | Novo Nordisk A/S | Use of liver-selective glucokinase activators |
| AU2005291810B2 (en) | 2004-10-07 | 2011-12-08 | Stem Cell Therapeutics Corp. | Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds |
| WO2006110809A2 (en) | 2005-04-12 | 2006-10-19 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
| US20100028439A1 (en) | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| JP2009500378A (ja) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素 |
| JP2009500377A (ja) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | ジシクロアルキルウレア型グルコキナーゼ活性化剤 |
| JP4960355B2 (ja) | 2005-07-14 | 2012-06-27 | ノボ・ノルデイスク・エー／エス | ウレア型グルコキナーゼ活性化剤 |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| JP2010515701A (ja) | 2007-01-09 | 2010-05-13 | ノボ・ノルデイスク・エー／エス | ウレアグルコキナーゼアクチベーター |
| AU2008204530B2 (en) | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
| WO2009054251A1 (ja) | 2007-10-25 | 2009-04-30 | Sanyo Electric Co., Ltd. | 発電装置 |
| JP5513492B2 (ja) | 2008-05-16 | 2014-06-04 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤 |
| PT2576524T (pt) | 2010-05-26 | 2017-11-17 | Vtv Therapeutics Llc | Resumo |
| EP2392575A1 (en) | 2010-06-04 | 2011-12-07 | LEK Pharmaceuticals d.d. | A novel synthetic approach to ß-aminobutyryl substituted compounds |
| IN2014DN09554A (enExample) | 2012-05-17 | 2015-07-17 | Transtech Pharma Llc | |
| CA2903433A1 (en) * | 2013-03-04 | 2014-09-12 | Vtv Therapeutics Llc | Stable glucokinase activator compositions |
| HK1213197A1 (zh) | 2013-03-04 | 2016-06-30 | Vtv治疗有限责任公司 | 包括葡糖激酶活化劑的固體組合物及其製備和使用方法 |
| JP6102611B2 (ja) | 2013-07-31 | 2017-03-29 | セイコーエプソン株式会社 | 液体噴射装置及びワイピング方法 |
| DK3556354T3 (da) * | 2016-12-15 | 2025-08-04 | Hua Medicine Shanghai Ltd | Oral fremstilling af en glucokinaseaktivator og fremgangsmåde til fremstilling deraf |
| CA3093025A1 (en) | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CA3181665A1 (en) | 2020-06-08 | 2021-12-16 | Jing TENG | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof |
| US12479808B2 (en) | 2020-06-08 | 2025-11-25 | Vtv Therapeutics Llc | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
-
2021
- 2021-06-07 US US18/000,907 patent/US12479808B2/en active Active
- 2021-06-07 WO PCT/US2021/036084 patent/WO2021252311A1/en not_active Ceased
- 2021-06-07 EP EP21822587.8A patent/EP4161640A4/en active Pending
- 2021-06-07 CN CN202511838345.9A patent/CN121591674A/zh active Pending
- 2021-06-07 CN CN202180056620.5A patent/CN116194442A/zh active Pending
- 2021-06-07 JP JP2023519157A patent/JP2023530786A/ja active Pending
- 2021-06-07 AU AU2021289309A patent/AU2021289309A1/en active Pending
- 2021-06-07 CA CA3181722A patent/CA3181722A1/en active Pending
- 2021-06-07 MX MX2022015525A patent/MX2022015525A/es unknown
- 2021-06-07 KR KR1020237000610A patent/KR20230048502A/ko active Pending
-
2022
- 2022-12-06 MX MX2025012174A patent/MX2025012174A/es unknown
- 2022-12-06 MX MX2025012175A patent/MX2025012175A/es unknown
-
2025
- 2025-10-29 US US19/372,916 patent/US20260217666A1/en active Pending
-
2026
- 2026-03-03 JP JP2026033600A patent/JP2026102669A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230219909A1 (en) | 2023-07-13 |
| CN116194442A (zh) | 2023-05-30 |
| US20260217666A1 (en) | 2026-07-30 |
| EP4161640A1 (en) | 2023-04-12 |
| JP2023530786A (ja) | 2023-07-19 |
| MX2025012175A (es) | 2025-11-03 |
| JP2026102669A (ja) | 2026-06-23 |
| US12479808B2 (en) | 2025-11-25 |
| MX2025012174A (es) | 2025-11-03 |
| AU2021289309A1 (en) | 2023-01-19 |
| WO2021252311A1 (en) | 2021-12-16 |
| CA3181722A1 (en) | 2021-12-16 |
| CN121591674A (zh) | 2026-03-03 |
| KR20230048502A (ko) | 2023-04-11 |
| EP4161640A4 (en) | 2024-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025012174A (es) | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxiciclohexil)ureido]tiazol-5-ilsulfanil}-acetico y usos de los mismos | |
| EP4491199A3 (en) | Gadolinium bearing pcta-based contrast agents | |
| CY1119076T1 (el) | Αλατα πιπεραζινης ως ανταγωνιστες των d3/d2 | |
| AR031944A1 (es) | Sal de fosfato del inhibidor de la oxido nitrico sintasa | |
| MY131525A (en) | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | |
| MY150784A (en) | Metabolites of (thio) carbamoyl-cyclohexane derivatives | |
| NO155805C (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter. | |
| PT998473E (pt) | Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao | |
| DE60234028D1 (de) | Hydantion-derivate als hemmer von matrix-metalloproteinasen | |
| CL2024000758A1 (es) | Sal de trometamina de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético | |
| ZA202213152B (en) | Novel acid secretion inhibitor and use thereof | |
| CY1110358T1 (el) | Υποκατεστημενα παραγωγα προπενυλ πιπεραζινης ως νεοι αναστολεις της αποακετυλασης ιστονης | |
| EA200971086A1 (ru) | Фармацевтические композиции и способ лечения шизофрении | |
| MX2021010906A (es) | Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas. | |
| PE20050329A1 (es) | Derivados de nicotinamida como inhibidores de fosfodiesterasa pde4 | |
| ZA202203360B (en) | Peptide amide composition and preparation method therefor | |
| PL431139A1 (pl) | Kompozycja farmaceutyczna bimatoprostu i tymololu | |
| ATE98237T1 (de) | Disubstituierte piperazine. | |
| MX2023003245A (es) | Derivados de amina novedosos. | |
| BRPI0607214B8 (pt) | derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação | |
| PH12021553110A1 (en) | Compounds for treating respiratory disease | |
| GB1417402A (en) | Pharmacologically active anilinobenzothiazoles | |
| HK40087135A (en) | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof | |
| CR20220644A (es) | Derivados de sulfona | |
| MX2021003375A (es) | Composiciones de rutina. |